Who is sponsoring NCT03591328?

NCT03591328 is sponsored by Seoul National University Hospital.

What drugs are being tested in NCT03591328?

Interventions in NCT03591328: Coronary CT angiography.

What condition does NCT03591328 study?

NCT03591328 studies Acute Myocardial Infarction, Unstable Angina.

Is NCT03591328 still recruiting?

NCT03591328 is currently status unknown. Last updated 23 August 2022.

Last reviewed 2022-08-23 · How we verify

NCT03591328: EMERALD II

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exploring the Mechanism of Plaque Rupture in Acute Coronary Syndrome Using Coronary CT Angiography and Computational Fluid Dynamics II (EMERALD II) Study

Status unknown Last updated 23 August 2022

What this trial tests

trial testing Coronary CT angiography in Acute Myocardial Infarction in 429 participants. Status unknown.

Timeline

9 July 2018

Primary endpoint
30 September 2022

31 December 2022

Quick facts

Lead sponsor	Seoul National University Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	429
Start date	9 July 2018
Primary completion	30 September 2022
Estimated completion	31 December 2022
Sites	1 location across South Korea

Drugs / interventions tested

Coronary CT angiography

Conditions studied

Acute Myocardial Infarction — all drugs for Acute Myocardial Infarction →
Unstable Angina — all drugs for Unstable Angina →

Sponsor

Seoul National University Hospital

Who can join

Eligibility, any sex, with Acute Myocardial Infarction or Unstable Angina. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The EMERALD II study is a multinational, multicenter, and retrospective study. ACS patients who underwent CCTA from 1 months to 3 years prior to the event will be retrospectively identified. Plaques in the non-culprit vessels will be regarded as a primary control group.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Artificial Intelligence-Enabled Quantitative Coronary Plaque and Hemodynamic Analysis for Predicting Acute Coronary Syndrome.
Koo BK, Yang S, Jung JW, Zhang J, et al · · 2024 · cited 51× · PMID 38752951 · DOI 10.1016/j.jcmg.2024.03.015
Risk stratification of coronary plaques using physiologic characteristics by CCTA: Focus on shear stress.
Samady H, Molony DS, Coskun AU, Varshney AS, et al · · 2020 · cited 23× · PMID 31870744 · DOI 10.1016/j.jcct.2019.11.012
Prognostic Time Frame of Plaque and Hemodynamic Characteristics and Integrative Risk Prediction for Acute Coronary Syndrome.
Yang S, Jung JW, Park SH, Zhang J, et al · · 2025 · cited 4× · PMID 40272335 · DOI 10.1016/j.jcmg.2025.02.003
Anatomical vs Physiological Lesion Characteristics in Prediction of Acute Coronary Syndrome.
Yang S, Chung JW, Park SH, Zhang J, et al · · 2025 · cited 1× · PMID 41371781 · DOI 10.1016/j.jcin.2025.09.006

Verify or expand the search:

Other trials of Coronary CT angiography

Trials testing the same drug.

NCT05413109 — COMPression of Left Main coRonary artEry in patientS With Pulmonary Arterial Hypertension aSymptomatIc fOr aNgina · NA · recruiting
NCT04073810 — Residual Inflammation and Plaque Progression Long-term Evaluation · active not recruiting
NCT05380622 — CHART Study of Coronary CT Angiography in Coronary Artery Disease · recruiting

Other recruiting trials for Acute Myocardial Infarction

Currently open trials in the same condition.

NCT03951467 — Using an Intervention Adapted to the Health Literacy Level to Improve Adherence to Medical Recommendations · NA · recruiting
NCT07536802 — Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention: A Randomized Control Trial · Phase 4 · recruiting
NCT06947135 — Stellate Ganglion Morphine Infiltration on Myocardial Ischemia-Reperfusion Injury · NA · recruiting
NCT06515730 — Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction · Phase 4 · recruiting
NCT07522164 — Acute Myocardial Infarction Clinical Cohort · active not recruiting

Other Seoul National University Hospital trials

Trials by the same sponsor.

NCT07262944 — EOI Block in Otoplasty With Rib Cartilage Graft · NA · recruiting
NCT07464210 — Nemtabrutinib, Bortezomib, and Rituximab for WM · Phase 2 · not yet recruiting
NCT07550803 — Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery · NA · not yet recruiting
NCT07522138 — Home-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study · NA · not yet recruiting
NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03591328 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Seoul National University Hospital
Last refreshed: 23 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03591328.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing